There has been a steady drumbeat of failure in the race to develop a third-generation EGFR inhibitor to compete with Tagrisso(osimertinib) from AstraZeneca (LSE: AZN) in an around $5 billion market.
Now Checkpoint Therapeutics, a Fortress Biotech (Nasdaq: FBIO) company, is gaining visibility. Checkpoint announced today that Phase I/II data from its third-generation EGFR inhibitor CK-101 has been selected for a late-breaking oral presentation at the International Association for the Study of Lung Cancer’s 19th World Conference on Lung Cancer, to be held September 23-26.
Other Big Pharmas have tried their hand at a third-generation therapy, but all real competition has failed:
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze